Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLINCOMYCIN HYDROCHLORIDE (lincomycin hydrochloride) by Pfizer is clinical pharmacology intramuscular administration of a single dose of 600 mg of lincomycin produces average peak serum concentrations of 11. Approved for the treatment of serious infections due to susceptible strains of streptococci, pneumococci, staphylococci and 2 more indications. First approved in 2021.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Intramuscular administration of a single dose of 600 mg of lincomycin produces average peak serum concentrations of 11.6 mcg/mL at 60 minutes and maintains therapeutic concentrations for 17 to 20 hours for most susceptible gram-positive organisms. Urinary excretion after this…
Worked on LINCOMYCIN HYDROCHLORIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Relative Bioavailability Study Of Two Lincomycin Hydrochloride Hard Gelatinous Capsule
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo